Loading news...
Low-beta picks gain focus as Iran war fears stir volatility. AGRO, PRA, E and LQDA reflect resilience with momentum, liquidity and fundamentals.
Does ProAssurance (PRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Shares of ProAssurance Corporation (NYSE: PRA - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the six analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1 year
PRA posts Q4 EPS of 82 cents, topping estimates as expenses fall and investment income rises despite lower premiums.
While the top- and bottom-line numbers for ProAssurance (PRA) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ProAssurance (PRA) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.36 per share a year ago.
BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $33.4 million, or $0.64 per diluted share, and operating income(1) of $42.4 million, or $0.82 per diluted share, for the three months ended December 31, 2025. For the year ended December 31, 2025, net income was $50.9 million, or $0.99 per diluted share, and operating income was $83.9 million, or $.
Credit Industriel ET Commercial trimmed its holdings in ProAssurance Corporation (NYSE: PRA) by 24.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 252,275 shares of the insurance provider's stock after selling 80,720 shares during the period. ProAssurance accounts for approximately 0.5%
ProAssurance Corporation (NYSE: PRA - Get Free Report) has earned an average rating of "Reduce" from the six brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a hold rating on the company. The average 1 year price objective among analysts that
ProAssurance Corporation (NYSE: PRA - Get Free Report) has earned a consensus rating of "Reduce" from the six brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average twelve-month price target among brokerages that have
Groupe la Francaise acquired a new stake in shares of ProAssurance Corporation (NYSE: PRA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 214,228 shares of the insurance provider's stock, valued at approximately $4,891,000. Groupe la Francaise owned about 0.42% of ProAssurance
Shares of ProAssurance Corporation (NYSE: PRA - Get Free Report) have been assigned an average recommendation of "Reduce" from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. The average 12 month
PRA misses Q3 EPS estimates as weak Specialty P&C results and higher costs outweigh gains in investment income.
The headline numbers for ProAssurance (PRA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ProAssurance (PRA) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.34 per share a year ago.
BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $1.4 million, or $0.03 per diluted share, and operating income(1) of $7.9 million, or $0.15 per diluted share, for the three months ended September 30, 2025. For the nine months ended September 30, 2025, net income was $17.5 million, or $0.34 per diluted share, and operating income was $41.5 millio.
Despite higher catastrophe losses, HRTG, PRA, and HCI not only outperform the industry but also crush the Zacks S&P 500 composite and Finance sector.
STRASBOURG, France, Aug. 13, 2025 /PRNewswire/ -- Qaelon Medical, a pioneer in real-time surgical leak detection and constant-flow insufflation technologies, today welcomed two new members to its Data Advisory Board (DAB): Shanna Cotti, industry Chief Information Officer, and Robert D. Francis, President, Medical Professional Liability, ProAssurance Corporation. Robert and Shanna join existing DAB members Professor David Jayne and Assistant Professor Amin Madani announced last month. The multidisciplinary board will guide Qaelon's data strategy with an initial focus on two areas: "We are thrilled to welcome Shanna and Rob to Qaelon's Data Advisory Board," said Eran Shlomovitz, MD, FRCPC, FRCSC, FACS, Chief Medical Officer and Founder of Qaelon Medical. "Their deep expertise and insight will help ensure our technology is optimally deployed to save lives and reduce healthcare costs by establishing the first standardized, data-driven test methodology for surgical leak detection." Data-Driven Surgical Leak DetectionQaelon's proprietary leak detection system, the first to provide quantifiable, EMR-exportable leak assessments via a proprietary constant-flow insufflator, delivers objective insights in under 30 seconds. Validated in over 1,200 preclinical tests, it modernizes a century-old workflow, enabling surgeons to identify and address life-threatening leaks in real-time to reduce risks of sepsis, reoperation, or death. "We're bringing the standard for surgical leak testing into the digital age while expanding the ecosystem of the intelligent OR," said Liam Burns, CEO of Qaelon Medical. "With guidance from our Data Advisory Board, we're creating the first Objective Performance Indicator (OPI) for surgical leaks, which will enable AI-powered clinical decision-making support, while advancing a measurable, outcomes-focused standard of care." About Qaelon MedicalQaelon Medical is redefining leak detection in surgery. Its platform is the first and only system that combines real-time, AI-powered detection with precision insufflation, creating the foundation for intraoperative surgical intelligence. Headquartered in Strasbourg, France, Qaelon is backed by industry veterans, strategic partners like Caresyntax, and a global network of clinical innovators. For more information, visit www.qaelonmedical.com or contact [email protected].
PRA's Q2 earnings top estimates as lower expenses and higher investment income offset weaker premiums.